Cargando…

Effective Crizotinib schedule for an elderly patient with ALK rearranged non-small-cell lung cancer: a case report

BACKGROUND: Non-small-cell lung cancers (NSCLCs) harboring translocations in anaplastic lymphoma kinase (ALK) are highly sensitive to small-molecule ALK kinase inhibitors, such as crizotinib. CASE PRESENTATION: We describe a case of post-operative local recurrence of lung adenocarcinoma in an 81 yea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fukuizumi, Aya, Miyanaga, Akihiko, Seike, Masahiro, Kato, Yasuhiro, Nakamichi, Shinji, Chubachi, Kumi, Matsumoto, Masaru, Noro, Rintaro, Minegishi, Yuji, Kunugi, Shinobu, Kubota, Kaoru, Gemma, Akihiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4415237/ https://www.ncbi.nlm.nih.gov/pubmed/25899913 http://dx.doi.org/10.1186/s13104-015-1126-8

Ejemplares similares

Overcoming drug-tolerant cancer cell subpopulations showing AXL activation and epithelial–mesenchymal transition is critical in conquering ALK-positive lung cancer
por: Nakamichi, Shinji, et al.
Publicado: (2018)

Remarkable Clinical Response of ALK-Rearranged/TP53-Mutant Lung Adenocarcinoma with Liver Metastasis to Atezolizumab-Bevacizumab-Carboplatin-Paclitaxel After ALK Inhibitors: A Case Report
por: Iso, Hirokazu, et al.
Publicado: (2023)

Carboplatin plus nanoparticle albumin-bound paclitaxel for the treatment of thymic carcinoma
por: Takahashi, Akiko, et al.
Publicado: (2022)

Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer
por: Takahashi, Akiko, et al.
Publicado: (2018)

Alectinib-Induced Severe Hemolytic Anemia in a Patient with ALK-Positive Non-Small Cell Lung Cancer: A Case Report
por: Misawa, Kazuhito, et al.
Publicado: (2023)

Efficacy with Trastuzumab Deruxtecan for Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutation in a Patient with a Poor Performance Status: A Case Report
por: Kato, Yuki, et al.
Publicado: (2021)

Osimertinib early dose reduction as a risk to brain metastasis control in EGFR‐mutant non‐small cell lung cancer
por: Tozuka, Takehiro, et al.
Publicado: (2023)

CADM1 and SPC25 Gene Mutations in Lung Cancer Patients With Idiopathic Pulmonary Fibrosis
por: Fukuizumi, Aya, et al.
Publicado: (2021)

Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4–ALK-rearranged non–small–cell lung cancer harbored coexisting EGFR mutation
por: Miyanaga, Akihiko, et al.
Publicado: (2013)

Inhibitors of ABCB1 and ABCG2 overcame resistance to topoisomerase inhibitors in small cell lung cancer
por: Omori, Miwako, et al.
Publicado: (2022)

Successful Treatment with Short-Term Steroid Against Severe Hepatitis Confirmed by Liver Biopsy in a Patient with Advanced Squamous-Cell Lung Cancer Receiving a Combination of Pembrolizumab, Carboplatin, and Nab-Paclitaxel: A Case Report
por: Hayashi, Anna, et al.
Publicado: (2022)

Control of the MYC-eIF4E axis plus mTOR inhibitor treatment in small cell lung cancer
por: Matsumoto, Masaru, et al.
Publicado: (2015)

miR-200/ZEB axis regulates sensitivity to nintedanib in non-small cell lung cancer cells
por: NISHIJIMA, NOBUHIKO, et al.
Publicado: (2016)

The respiratory microbiome associated with chronic obstructive pulmonary disease comorbidity in non‐small cell lung cancer
por: Shimizu, Masamitsu, et al.
Publicado: (2022)

Neoadjuvant crizotinib in ALK-rearranged inflammatory myofibroblastic tumor of the urinary bladder: A case report
por: Nagumo, Yoshiyuki, et al.
Publicado: (2018)

Bevacizumab plus chemotherapy in nonsquamous non‐small cell lung cancer patients with malignant pleural effusion uncontrolled by tube drainage or pleurodesis: A phase II study North East Japan Study group trial NEJ013B
por: Noro, Rintaro, et al.
Publicado: (2020)

Successful Treatment with Afatinib after Osimertinib-induced Interstitial Lung Disease in a Patient with EGFR-mutant Non-small-cell Lung Cancer
por: Nishima, Shunichi, et al.
Publicado: (2020)

Pembrolizumab-induced agranulocytosis in a pulmonary pleomorphic carcinoma patient who developed interstitial lung disease and ocular myasthenia gravis
por: Tozuka, Takehiro, et al.
Publicado: (2018)

Immune checkpoint inhibitor‐associated interstitial lung diseases correlate with better prognosis in patients with advanced non‐small‐cell lung cancer
por: Sugano, Teppei, et al.
Publicado: (2020)

Predictive Impact of Diffuse Positivity for TTF-1 Expression in Patients Treated With Platinum-Doublet Chemotherapy Plus Immune Checkpoint Inhibitors for Advanced Nonsquamous NSCLC
por: Terashima, Yuto, et al.
Publicado: (2023)

Pembrolizumab and salvage chemotherapy in EGFR T790M-positive non-small-cell lung cancer with high PD-L1 expression
por: Tozuka, Takehiro, et al.
Publicado: (2018)

Long Non-Coding RNA CRNDE Is Involved in Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutant Lung Cancer via eIF4A3/MUC1/EGFR Signaling
por: Takahashi, Satoshi, et al.
Publicado: (2021)

NCOA1–ALK: a novel ALK rearrangement in one lung adenocarcinoma patient responding to crizotinib treatment
por: Cao, Qi, et al.
Publicado: (2019)

MET FISH-positive status predicts short progression-free survival and overall survival after gefitinib treatment in lung adenocarcinoma with EGFR mutation
por: Noro, Rintaro, et al.
Publicado: (2015)

Anaplastic lymphoma kinase (ALK)-rearranged pulmonary pleomorphic carcinoma successfully treated with crizotinib
por: Lin, Liping, et al.
Publicado: (2018)

Crizotinib efficacy in advanced non-squamous NSCLC patients with ALK or ROS1 rearrangement
por: Krawczyk, Paweł, et al.
Publicado: (2021)

Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial
por: Mansfield, A. S., et al.
Publicado: (2022)

Standard versus low‐dose nab‐paclitaxel in previously treated patients with advanced non‐small cell lung cancer: A randomized phase II trial (JMTO LC14‐01)
por: Takeuchi, Susumu, et al.
Publicado: (2023)

Oral rehydration solution (OS-1) as a substitute of intravenous hydration after cisplatin administration in patients with lung cancer: a prospective multicenter trial
por: Horinouchi, Hidehito, et al.
Publicado: (2018)

A case of interstitial lung disease with alveolar hemorrhage induced by pembrolizumab
por: Sugano, Teppei, et al.
Publicado: (2018)

Dual drive coexistence of ALK rearrangement and KRAS mutation advanced lung adenocarcinoma and response to crizotinib
por: Zhu, You-Cai, et al.
Publicado: (2019)

Marked improvement in leptomeningeal carcinomatosis and spinal cord metastases following alectinib treatment of crizotinib-resistant, ALK-positive lung adenocarcinoma
por: Kuribayashi, Hidehiko, et al.
Publicado: (2015)

ALK(G1269A) mutation as a potential mechanism of acquired resistance to crizotinib in an ALK-rearranged inflammatory myofibroblastic tumor
por: Michels, Sebastian Y. F., et al.
Publicado: (2017)

Acute respiratory failure due to Aspergillus niger infection with acute fibrinous and organazing pneumonia: A case report
por: Okamura, Ken, et al.
Publicado: (2022)

Case report: Durable response to alectinib in ALK-rearranged lung adenocarcinoma with acquired, crizotinib-resistant ALK C1156F mutation
por: Rao, Chuangzhou, et al.
Publicado: (2022)

Early pneumothorax as a feature of response to crizotinib therapy in a patient with ALK rearranged lung adenocarcinoma
por: Gennatas, Spyridon, et al.
Publicado: (2013)

Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression
por: Chen, Rui-Lian, et al.
Publicado: (2018)

Clinical features and outcomes of ALK rearranged non‐small cell lung cancer with primary resistance to crizotinib
por: Ma, Di, et al.
Publicado: (2019)

Intralymphatic histiocytosis in a patient with lung adenocarcinoma treated with pembrolizumab: a case report
por: Sugano, Teppei, et al.
Publicado: (2019)

Successful Desensitization with Crizotinib after Crizotinib-induced Liver Injury in ROS1-rearranged Lung Adenocarcinoma
por: Ota, Takayo, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_aiobn5f98n9kmsl64gd44hs1it